These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 28649611)

  • 1. LRRK2 levels in immune cells are increased in Parkinson's disease.
    Cook DA; Kannarkat GT; Cintron AF; Butkovich LM; Fraser KB; Chang J; Grigoryan N; Factor SA; West AB; Boss JM; Tansey MG
    NPJ Parkinsons Dis; 2017; 3():11. PubMed ID: 28649611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson's disease patients.
    Atashrazm F; Hammond D; Perera G; Bolliger MF; Matar E; Halliday GM; Schüle B; Lewis SJG; Nichols RJ; Dzamko N
    Mov Disord; 2019 Mar; 34(3):406-415. PubMed ID: 30597610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
    Gillardon F; Schmid R; Draheim H
    Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNL151, DNL201, and BIIB094: experimental agents for the treatment of Parkinson's disease.
    Müller T
    Expert Opin Investig Drugs; 2023; 32(9):787-792. PubMed ID: 37755071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous
    MacIsaac S; Quevedo Melo T; Zhang Y; Volta M; Farrer MJ; Milnerwood AJ
    Brain Commun; 2020; 2(1):fcz052. PubMed ID: 32510053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leucine-Rich Repeat Kinase 2 Influences Fate Decision of Human Monocytes Differentiated from Induced Pluripotent Stem Cells.
    Speidel A; Felk S; Reinhardt P; Sterneckert J; Gillardon F
    PLoS One; 2016; 11(11):e0165949. PubMed ID: 27812199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-γ induces leucine-rich repeat kinase LRRK2 via extracellular signal-regulated kinase ERK5 in macrophages.
    Kuss M; Adamopoulou E; Kahle PJ
    J Neurochem; 2014 Jun; 129(6):980-7. PubMed ID: 24479685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leucine-rich repeat kinase 2 modulates cyclooxygenase 2 and the inflammatory response in idiopathic and genetic Parkinson's disease.
    Lopez de Maturana R; Aguila JC; Sousa A; Vazquez N; Del Rio P; Aiastui A; Gorostidi A; Lopez de Munain A; Sanchez-Pernaute R
    Neurobiol Aging; 2014 May; 35(5):1116-24. PubMed ID: 24360742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism.
    van Nuenen BF; Helmich RC; Ferraye M; Thaler A; Hendler T; Orr-Urtreger A; Mirelman A; Bressman S; Marder KS; Giladi N; van de Warrenburg BP; Bloem BR; Toni I;
    Brain; 2012 Dec; 135(Pt 12):3687-98. PubMed ID: 23250886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor treatment of peripheral mononuclear cells from Parkinson's disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker.
    Perera G; Ranola M; Rowe DB; Halliday GM; Dzamko N
    Sci Rep; 2016 Aug; 6():31391. PubMed ID: 27503089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonic Leucine-Rich Repeat Kinase 2 Expression Is Increased and Associated With Disease Severity in Patients With Parkinson's Disease.
    Liao PH; Chiang HL; Shun CT; Hang JF; Chiu HM; Wu MS; Lin CH
    Front Aging Neurosci; 2021; 13():819373. PubMed ID: 35126095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes.
    Wallings RL; Hughes LP; Staley HA; Simon ZD; McFarland NR; Alcalay RN; Garrido A; Martí MJ; Sarró ET; Dzamko N; Tansey MG
    Front Cell Neurosci; 2022; 16():892899. PubMed ID: 35755775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leucine-Rich Repeat Kinase 2 in Parkinson's Disease: Updated from Pathogenesis to Potential Therapeutic Target.
    Chen J; Chen Y; Pu J
    Eur Neurol; 2018; 79(5-6):256-265. PubMed ID: 29705795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
    Kethiri RR; Bakthavatchalam R
    Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 and Parkinson's disease.
    Kang UB; Marto JA
    Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27723254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 levels and phosphorylation in Parkinson's disease brain and cases with restricted Lewy bodies.
    Dzamko N; Gysbers AM; Bandopadhyay R; Bolliger MF; Uchino A; Zhao Y; Takao M; Wauters S; van de Berg WD; Takahashi-Fujigasaki J; Nichols RJ; Holton JL; Murayama S; Halliday GM
    Mov Disord; 2017 Mar; 32(3):423-432. PubMed ID: 27911006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.